MEETINGS WITH EUROPEAN PARLIAMENTARIANS
Biofuels has been seen a renewable energy resource which represent a new opportunity for agriculture and industry. In both the industrialized and in the developing countries there is an increasing demand for alternative fuels due to the high prices of oil. Stavros Dimas, the European Commissioner responsible for the environment, has requested focus on making “credible and serious choices about biofuels”. He notes that the EU target of 10% of energy from biofuels would require us to divert 72% of our arable land with the current technology. Large scale biofuels production has also been cited as a threat to world food security. Does it make sense scientifically and economically to produce biofuels from agricultural products? What are the longer term perspectives for Europe and the rest of the world concerning this new source of energy?
The European Parliament, May 15, 2008 The panel of the EAGLES hearing from left: Richard James Murphy, Kirsten Birkegaard Stær, Willy De Greef, David McConnell, Britta Thomsen and Keith Smith.
Download Presentations (PDF) by:
An EAGLES meeting for Members of the European Parliament (MEP) and other stakeholders in Brussels gave very good response from the MEPs and the Commission. A mechanism for measuring how much the developing world is participating in the 7th Framework Programme was suggested. The MEPs are now well aware of the EAGLES target line of 5% research money to developing world about 2.850 M€ in the 7th Framework Programme budget.
Jerzy Buzek, Former President of Poland, Rapporteur on EU-Parliament FP7 Programme talking at EAGLES meeting in Brussels 2006.
This dinner meeting counted with the participation of 16 MEPs and around 35 other important stakeholders interested in developing world research. The meeting was hosted by MEP Britta Thomsen.
of current EAGLES activities
on Science, Technology and the developing world
Fisheries indicators ‘too narrow’ to show real impact
Conversion of coconut gene farms threatens diversity
First African antimalarial to enter clinical trial